E2108 Primary Analysis Clinical Data Description

The clinicaltrials.gov protocol identifier: NCT01242800 This data dictionary is for the NCT01242800-D1 dataset.

The data in the spreadsheet are the clinical analysis data for the primary manuscript on E2108 results, published in

Khan SA, Zhao F, Goldstein LJ, Cella D, Basik M, Golshan M, Julian TB, Pockaj BA, Lee CA, Razaq W, Sparano JA, Babiera GV, Dy IA, Jain S, Silverman P, Fisher CS, Tevaarwerk AJ, Wagner LI, Sledge GW. Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108). *J Clin Oncol*. 2022 Mar 20;40(9):978-987.PMCID: PMC8937009.

The data reflect the study database as of December 10, 2019. It includes all patients registered to the Step 1 of the trial.

Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Data File Description

Field	Variable Name	Description	Coding	Note
1				De-identified patient ID
	uid	Patient identifier		
2	step	Indicator for whether the patient was randomized to step 2	0=Off study at step 1, 1=Randomized to step 2	
3	elig_step1	Met eligibility criteria for step 1	0=No, 1=Yes	
4		Age at study registration (years) to		
	age1	step 1	Continuous variable	
5	gender	Sex	1=Male, 2=Female	
6	race	Race	1=White, 2=Black, 3=Other	
7	ethn	Ethnicity	1=Non-Hispanic, 2=Hispanic	
8	menopausal_stat1	Menopausal status at step 1	1=Postmenopausal, 2=Premenopausal, 3=Perimenopausal	

Field	Variable Name	Description	Coding	Note
9	subtype	Tumor subtuno	1=HR-positive and HER2-negative,	
10	subtype	Tumor subtype	2=Triple-negative, 3=HER2-positive	
10	metasite1	Metastatic sites at step 1	1=Visceral only, 2=Bone only, 3=Soft tissue only, 4=Multiple sites	
11	illetasiter	Wetastatic sites at step 1	tissue only, 4–ividitiple sites	The 384 patients who had
				assessable site of disease had
	oligo	Oligomets	0=No, 1=Yes	value for this variable.
12	stage	Primary tumor stage	1=T1-3 and N0-1, 2=T4 and/or N2-3	
13	invasion_yn	Direct invasion of tumor into skin	1=No, 2=Yes	
14	nod_prsnt_yn	(Breast) Skin nodules present	1=No, 2=Yes	
15			1=Free, 2=Attached to fascia, 3=Chest	
	tum_loc	Tumor mobility	wall fixation	
16		Indicator whether patient reported		
		optimal systemic therapy (OST)		
	OSTdata	data	0=No, 1=Yes	
17		Daniel OCT a death and all		Only applicable for the 374
	OCT timin	Began OST prior to study	0 No 1 Yes	patients who reported OST data.
10	OST_timing	registration	0=No, 1=Yes	0.1
18			1=Chemo alone,	Only applicable for the 374
			2=Endocrine therapy alone, 3=Both endocrine and chemotherapy,	patients who reported OST data.
		OST treatment regimen	4=Chemotherapy with HER2-directed	
	OST_group	combination	therapy	
19			therapy	Only applicable for the 374
		OST treatment duration in weeks		patients who reported OST data.
	OST_week	after study registration	Continuous variable	·
20			1=Disease progression, 2=Patient	Only the 134 patients who went
			withdrawal, 3=Unsuitable for surgery,	off study after step 1 had value
		Reason for discontinuing protocol	4=Death on study, 5=Ineligible for	for this variable.
	off_tx_reas	therapy at Step 1	random assignment, 99=Other reason	
21		Overall survival (OS) status for		As of database on 12/10/2019,
	surv_s1	patients off treatment at Step 1	0=Censored, 1=Died	only the 134 patients who went

Field	Variable Name	Description	Coding	Note
				off study after step 1 had value for this variable.
22	surv_m1	OS time in months for patients off treatment at Step 1	Continuous variable	As of database on 12/10/2019, only the 134 patients who went off study after step 1 had value for this variable.
23	cod_step1	Cause of death	2=Breast cancer, 3=Other disease, 9=Cause unknown	As of database on 12/10/2019, only the patients who went off study at step 1 and died had value for this variable.
24	trtm	Treatment arm at Step 2	A=Continued systemic therapy, B=Early local therapy	The 256 patients who were randomized to step 2 had value for this variable

Notes:

- Unless otherwise specified, blank values indicate missing data.
- In the analysis, months were calculated as number of days/30.4375.
- The data in this dataset that are reported in Supplemental Table 1 are further cleaned since publication.